Clinical Trials Logo

Treatment Resistant Disorders clinical trials

View clinical trials related to Treatment Resistant Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05243329 Active, not recruiting - Clinical trials for Post Traumatic Stress Disorder

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Start date: October 3, 2022
Phase: Phase 2
Study type: Interventional

Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.